Chris Burns
@ampliaceo.bsky.social
CEO of Amplia Therapeutics, a Melbourne, Australia, based biotech developing a pipeline of small molecule FAK inhibitors for cancer and fibrotic diseases. Our lead asset is narmafotinib currently in a Phase 2a trial in pancreatic cancer (NCT05355298).
Triple negative breast cancer remains tough to treat. A new study finds FAK interacts with PD-L1, boosting immune evasion when inhibited. Combining FAK inhibitors with PD-L1 blockade could unlock better therapies.
www.mdpi.com/3547364
#FAK #TNBC #Immunotherapy
www.mdpi.com/3547364
#FAK #TNBC #Immunotherapy
www.mdpi.com
November 15, 2025 at 6:33 AM
Triple negative breast cancer remains tough to treat. A new study finds FAK interacts with PD-L1, boosting immune evasion when inhibited. Combining FAK inhibitors with PD-L1 blockade could unlock better therapies.
www.mdpi.com/3547364
#FAK #TNBC #Immunotherapy
www.mdpi.com/3547364
#FAK #TNBC #Immunotherapy
Breakthrough Victoria commits $75m to VC funds www.innovationaus.com/breakthrough...
Breakthrough Victoria commits $75m to VC funds
The Victorian government has made a $75 million investment through Breakthrough Victoria into five venture capital funds, aimed at boosting private capital, supporting early-stage companies and accele...
www.innovationaus.com
October 27, 2025 at 10:17 PM
Breakthrough Victoria commits $75m to VC funds www.innovationaus.com/breakthrough...
Adelaide scientists have identified the cell surface receptor F2R as a promising biomarker and treatment target for ovarian cancer. This breakthrough could improve diagnosis and therapy for women with this deadly disease, especially those with drug-resistant cancers. www.mdpi.com/3481014
www.mdpi.com
October 27, 2025 at 9:57 PM
Adelaide scientists have identified the cell surface receptor F2R as a promising biomarker and treatment target for ovarian cancer. This breakthrough could improve diagnosis and therapy for women with this deadly disease, especially those with drug-resistant cancers. www.mdpi.com/3481014
New research finds that targeting mechanoresponsive myeloid cells through FAK inhibition reduces fibrosis and scarring by restoring anti-inflammatory cell populations—offering fresh hope for systemic therapies against organ fibrosis. #FAK #Fibrosis #Immunology rdcu.be/eMOrH
Targeting circulating mechanoresponsive monocytes and macrophages to reduce fibrosis
Nature Biomedical Engineering - Myeloid-specific mechanotransduction ablation downregulates pro-fibrotic fibroblast transcriptional profiles to reduce scar formation in human cells
rdcu.be
October 26, 2025 at 9:38 PM
New research finds that targeting mechanoresponsive myeloid cells through FAK inhibition reduces fibrosis and scarring by restoring anti-inflammatory cell populations—offering fresh hope for systemic therapies against organ fibrosis. #FAK #Fibrosis #Immunology rdcu.be/eMOrH
#Amplia is expanding its U.S. presence to boost investor awareness & engagement. As its Phase 1b/2a AMPLICITY trial continues in the U.S. and Australia, Amplia has launched a U.S. capital markets campaign and is pursuing an OTCQB uplisting. bit.ly/3IRUrmV $ATX #clinicaltrials #pancreaticcancer
ASX:ATX - Amplia Therapeutics to Significantly Expand U.S. Presence
Read and interact with this announcement: Amplia Therapeutics to Significantly Expand U.S. Presence on Amplia's investor hub
bit.ly
October 17, 2025 at 1:44 AM
#Amplia is expanding its U.S. presence to boost investor awareness & engagement. As its Phase 1b/2a AMPLICITY trial continues in the U.S. and Australia, Amplia has launched a U.S. capital markets campaign and is pursuing an OTCQB uplisting. bit.ly/3IRUrmV $ATX #clinicaltrials #pancreaticcancer
New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: bit.ly/3IQavFG
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma
October 8, 2025 at 11:23 PM
New Data | Amplia’s ongoing ACCENT clinical trial in advanced pancreatic cancer has recorded an additional confirmed partial response and one unconfirmed partial response. Read the ASX release: bit.ly/3IQavFG
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma
$ATX $INNMF #Amplia #clinicaltrial #pancreaticcancer #innovation #pharma
As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity www.statnews.com/2025/09/25/m... via @statnews.com
As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity
As the U.S. dials back mRNA research, the U.K. is trying to seize an opportunity.
www.statnews.com
September 26, 2025 at 1:16 PM
As the U.S. dials back mRNA research, the U.K. tries to seize an opportunity www.statnews.com/2025/09/25/m... via @statnews.com
The diagnosis that saved me — and may have misled my mother to her death www.statnews.com/2025/09/10/m... via @statnews.com
The diagnosis that saved me — and may have misled my mother to her death
If I had not survived a rare misdiagnosis, would my mother have fought harder for her own treatment?
www.statnews.com
September 13, 2025 at 6:22 AM
The diagnosis that saved me — and may have misled my mother to her death www.statnews.com/2025/09/10/m... via @statnews.com
Reposted by Chris Burns
🔓Read recent #OpenAccess work by Daohong Zhou, Guangrong Zheng & co on the potential of CRBN-recruiting Bcl-xL degraders as promising anticancer agents with improved efficacy and manageable platelet toxicity🔥
pubs.rsc.org/en/content/a...
📍 @ufresearch.bsky.social 🧪
pubs.rsc.org/en/content/a...
📍 @ufresearch.bsky.social 🧪
Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader
The conversion of conventional inhibitors of Bcl-xL, a key anti-apoptotic protein, to PROTAC degraders has shown significant promise, particularly in mitigating the on-target thrombocytopenia…
pubs.rsc.org
September 1, 2025 at 9:01 AM
🔓Read recent #OpenAccess work by Daohong Zhou, Guangrong Zheng & co on the potential of CRBN-recruiting Bcl-xL degraders as promising anticancer agents with improved efficacy and manageable platelet toxicity🔥
pubs.rsc.org/en/content/a...
📍 @ufresearch.bsky.social 🧪
pubs.rsc.org/en/content/a...
📍 @ufresearch.bsky.social 🧪
$72m boost for Australian medical research www.innovationaus.com/72m-boost-fo...
$72m boost for Australian medical research
More than $72 million in new medical research grants for projects ranging from chronic disease prevention and health equity to artificial intelligence in hospitals were announced by the federal govern...
www.innovationaus.com
September 1, 2025 at 10:05 PM
$72m boost for Australian medical research www.innovationaus.com/72m-boost-fo...
Reposted by Chris Burns
Two WEHI-led projects tackling Parkinson’s and acute myeloid leukaemia have each received $3m in NHMRC funding over five years as newly announced Centres of Research Excellence.
🔗 Learn more and meet the project leads: www.wehi.edu.au/news/6m-boos...
🔗 Learn more and meet the project leads: www.wehi.edu.au/news/6m-boos...
August 31, 2025 at 11:50 PM
Two WEHI-led projects tackling Parkinson’s and acute myeloid leukaemia have each received $3m in NHMRC funding over five years as newly announced Centres of Research Excellence.
🔗 Learn more and meet the project leads: www.wehi.edu.au/news/6m-boos...
🔗 Learn more and meet the project leads: www.wehi.edu.au/news/6m-boos...
Amplia has announced opening of two Australian trial sites for the Company’s new pancreatic cancer trial investigating narmafotinib with FOLFIRINOX in metastatic pancreatic cancer patients.
Read the ASX release: bit.ly/ATX-Sites-Open
#pancreaticcancer #clinicaltrial #FOLFORINOX #FAK
Read the ASX release: bit.ly/ATX-Sites-Open
#pancreaticcancer #clinicaltrial #FOLFORINOX #FAK
ASX:ATX - AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL
Read and interact with this announcement: AUSTRALIAN TRIAL SITES OPEN FOR NEW NARMAFOTINIB TRIAL on Amplia's investor hub
bit.ly
August 29, 2025 at 7:27 AM
Amplia has announced opening of two Australian trial sites for the Company’s new pancreatic cancer trial investigating narmafotinib with FOLFIRINOX in metastatic pancreatic cancer patients.
Read the ASX release: bit.ly/ATX-Sites-Open
#pancreaticcancer #clinicaltrial #FOLFORINOX #FAK
Read the ASX release: bit.ly/ATX-Sites-Open
#pancreaticcancer #clinicaltrial #FOLFORINOX #FAK
Let’s not waste our multibillion-dollar biotech opportunity www.innovationaus.com/lets-not-was...
Let's not waste our multibillion-dollar biotech opportunity
Australia’s life sciences industry is a quiet and unfortunately, regularly misunderstood achiever. With billions in annual revenues, the sector not only delivers world-class research, it also provides...
www.innovationaus.com
August 19, 2025 at 11:47 PM
Let’s not waste our multibillion-dollar biotech opportunity www.innovationaus.com/lets-not-was...
Great to see this work, using Starpharma's drug, published.
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1...
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1...
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors
PURPOSEThis early-phase study evaluated safety/tolerability, pharmacokinetics, and preliminary
efficacy of dendrimer-nanoparticle delivery platform (DEP)-SN38, a polylysine-based
nanoparticle conjugat...
ascopubs.org
August 7, 2025 at 7:40 AM
Great to see this work, using Starpharma's drug, published.
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1...
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors | Journal of Clinical Oncology ascopubs.org/doi/abs/10.1...
Reposted by Chris Burns
Are you a top US-based scientist wanting to relocate to Australia? We are now calling for formal applications from both Australian and non-Australian citizens based in the US whose work is internationally recognised as exceptional.
📅 Applications close: Aug 29, 2025
🔗 science.org.au/gtap/?utm_so...
📅 Applications close: Aug 29, 2025
🔗 science.org.au/gtap/?utm_so...
July 11, 2025 at 12:21 AM
Are you a top US-based scientist wanting to relocate to Australia? We are now calling for formal applications from both Australian and non-Australian citizens based in the US whose work is internationally recognised as exceptional.
📅 Applications close: Aug 29, 2025
🔗 science.org.au/gtap/?utm_so...
📅 Applications close: Aug 29, 2025
🔗 science.org.au/gtap/?utm_so...
This is great news, though can't help to wonder where is BioCurate?
Monash’s $15m pre-seed fund backs first spinouts www.innovationaus.com/monashs-15m-...
Monash’s $15m pre-seed fund backs first spinouts www.innovationaus.com/monashs-15m-...
Monash's $15m pre-seed fund backs first spinouts
Three Victorian HealthTech startups have secured pre-seed funding from Breakthrough Victoria and Monash University, marking the official launch of a new $15 million fund and the university’s new comme...
www.innovationaus.com
August 3, 2025 at 11:38 PM
This is great news, though can't help to wonder where is BioCurate?
Monash’s $15m pre-seed fund backs first spinouts www.innovationaus.com/monashs-15m-...
Monash’s $15m pre-seed fund backs first spinouts www.innovationaus.com/monashs-15m-...
Amplia has announced that it has received Australian ethics approval for the Ph2 trial of narmafotinib in combination with FOLFIRINOX in advanced pancreatic cancer.
Read the ASX release: bit.ly/ATX_AU_Ethics
$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics
Read the ASX release: bit.ly/ATX_AU_Ethics
$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics
July 30, 2025 at 3:53 AM
Amplia has announced that it has received Australian ethics approval for the Ph2 trial of narmafotinib in combination with FOLFIRINOX in advanced pancreatic cancer.
Read the ASX release: bit.ly/ATX_AU_Ethics
$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics
Read the ASX release: bit.ly/ATX_AU_Ethics
$ATX #Amplia #clinicaltrials #pancreaticcancer #cancertherapeutics
Excellent news!!!
Qld super mandate directs $50m to local startups www.innovationaus.com/qld-super-ma...
Qld super mandate directs $50m to local startups www.innovationaus.com/qld-super-ma...
Qld super mandate directs $50m to local startups
A new $50 million investment mandate will see Queenslanders’ retirement savings channelled back into the state’s economy, with Brighter Super and Queensland Investment Corporation joining forces to ba...
www.innovationaus.com
July 29, 2025 at 2:22 AM
Excellent news!!!
Qld super mandate directs $50m to local startups www.innovationaus.com/qld-super-ma...
Qld super mandate directs $50m to local startups www.innovationaus.com/qld-super-ma...
Amplia Therapeutics has announced 17th confirmed partial response (PR) has been recorded in the Company’s ongoing ACCENT clinical trial in pancreatic cancer. Read the ASX release: bit.ly/ATX_17th_PR
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
bit.ly
July 11, 2025 at 1:57 AM
Amplia Therapeutics has announced 17th confirmed partial response (PR) has been recorded in the Company’s ongoing ACCENT clinical trial in pancreatic cancer. Read the ASX release: bit.ly/ATX_17th_PR
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
Reposted by Chris Burns
This week's front cover features a Review by Taebo Sim and colleagues on the recent developments in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma, read it here👀
pubs.rsc.org/en/content/a...
📍Korea University and Yonsei University 🧪
pubs.rsc.org/en/content/a...
📍Korea University and Yonsei University 🧪
June 19, 2025 at 10:42 AM
This week's front cover features a Review by Taebo Sim and colleagues on the recent developments in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma, read it here👀
pubs.rsc.org/en/content/a...
📍Korea University and Yonsei University 🧪
pubs.rsc.org/en/content/a...
📍Korea University and Yonsei University 🧪
#Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release tinyurl.com/33ez5srv
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
Amplia Therapeutics Limited
Read and interact with this announcement: Second Complete Response in ACCENT Pancreatic Cancer Trial on Amplia's investor hub
tinyurl.com
June 19, 2025 at 6:56 AM
#Amplia has announced that a second patient enrolled in the ACCENT trial has recorded a confirmed complete response (CR). Read the ASX release tinyurl.com/33ez5srv
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
#pancreaticcancer #clinicaltrial #cancertherapeutics #oncology #pharma #biotech #ASX
I'll be speaking about narmafotinib and pipeline progress at #TwilightInvestorBriefing in Melbourne July 9th.
🔗 RSVP now: bit.ly/reg-twilight-ptx-atx
#ASX #biotech #oncology #pancreaticcancer
🔗 RSVP now: bit.ly/reg-twilight-ptx-atx
#ASX #biotech #oncology #pancreaticcancer
Registration | Twilight with PTX & ATX
Date: Wed, 9 July 2025
Time: 4.15pm arrival for 4.30pm start
Venue: Detail to be provided upon RSVP confirmation
Inquiry: info@monsoon.com.au
bit.ly
June 16, 2025 at 3:51 AM
I'll be speaking about narmafotinib and pipeline progress at #TwilightInvestorBriefing in Melbourne July 9th.
🔗 RSVP now: bit.ly/reg-twilight-ptx-atx
#ASX #biotech #oncology #pancreaticcancer
🔗 RSVP now: bit.ly/reg-twilight-ptx-atx
#ASX #biotech #oncology #pancreaticcancer
A patient from Amplia's ACCENT clinical trial in advanced pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the ASX release: bit.ly/ATX_pCR
$ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #ASX
$ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #ASX
Amplia Therapeutics Limited
Read and interact with this announcement: Pathological Complete Response in Pancreatic Cancer Trial on Amplia's investor hub
bit.ly
June 16, 2025 at 2:42 AM
A patient from Amplia's ACCENT clinical trial in advanced pancreatic cancer has now recorded a pathological complete response (pCR) - an extremely rare observation in this patient population. Read the ASX release: bit.ly/ATX_pCR
$ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #ASX
$ATX #Amplia #pancreaticcancer #clinicaltrial #pharma #biotech #ASX
Great to speak with Tim Boreham about Amplia Therapeutics' progress and plans. stockhead.com.au/health/dr-bo...
Dr Boreham's Crucible: This pancreatic cancer tackler has faith its 'good science will prevail' - Stockhead
Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.
stockhead.com.au
May 27, 2025 at 6:39 AM
Great to speak with Tim Boreham about Amplia Therapeutics' progress and plans. stockhead.com.au/health/dr-bo...